Max Healthcare Board Approves Grant of 2.15 Lakh Stock Options
Investywise
Last updated: May 20, 2026
Strides Pharma Science Limited has secured formal approval from the NCLT, Bengaluru Bench, for its scheme of arrangement. This scheme involves the demerger of its domestic formulations business into Strides Pharma Global Private Limited. The objective is to unlock value and create a more focused entity for the international business.
- Strides Pharma Science Limited's board had previously approved the demerger in March 2023. The approval from the National Company Law Tribunal (NCLT) is a significant step towards realizing this strategic restructuring. The domestic formulations business will be transferred to a wholly-owned subsidiary, Strides Pharma Global Private Limited.
- The demerger is intended to streamline operations and enhance the strategic focus of both the demerged entity and the remaining business of Strides Pharma Science Limited. This move is expected to unlock shareholder value by creating distinct, focused businesses. The international business, which includes the regulated markets, will remain with the parent company, allowing it to concentrate on its global growth strategies.
- The transaction is subject to other customary closing conditions and regulatory approvals. This restructuring aims to improve operational efficiency and market positioning for both parts of the business. The NCLT's approval signifies the legal completion of this critical phase in the arrangement.
